Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568003 · ClinicalTrials.gov registry record · NA
TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)
A NA study of Tricuspid Regurgitation (TR), sponsored by Jenscare Innovation.
- Active
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT06568003 is a NA study of Tricuspid Regurgitation (TR) that is active but no longer recruiting, run by Jenscare Innovation. The registered enrollment target is 15 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06568003, a NA study of Tricuspid Regurgitation (TR), is active but no longer recruiting, sponsored by Jenscare Innovation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
The LuX-Valve Plus System is intended for the treatment of patients with at least severe TR who are symptomatic and determined by a Heart Team not to be suitable for surgical treatment. This study aims to assess the safety and effectiveness of the LuX-Valve Plus System in high-surgical risk patients with at least severe tricuspid regurgitation (TR).
Conditions Studied
Interventions
- DEVICE Transcatheter Tricuspid Valve Intervention
Study Locations (3)
California
- Cedars-Sinai Medical Center - Los Angeles
Michigan
- Henry Ford Health System - Detroit
New York
- Montefiore Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-26 |
| Est. Completion | 2030-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06568003
The ClinicalTrials.gov registry entry for NCT06568003 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jenscare Innovation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tricuspid Regurgitation (TR) appearing as the primary indexed condition, and to 1 intervention - of which Transcatheter Tricuspid Valve Intervention is the first listed.
NCT06568003 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT06568003 about?
NCT06568003 is a clinical study titled "TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)". The LuX-Valve Plus System is intended for the treatment of patients with at least severe TR who are symptomatic and determined by a Heart Team not to be suitable for surgical treatment. This study aims to assess the safety and effectiveness of the LuX-Valve Plus System in high-surgical risk patients...
What is the current status of trial NCT06568003?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-09-26. Estimated completion is 2030-10.
What conditions does trial NCT06568003 study?
This clinical trial studies the following conditions: Tricuspid Regurgitation (TR).
What interventions are being tested in trial NCT06568003?
The interventions under investigation include: Transcatheter Tricuspid Valve Intervention (DEVICE).
Who is sponsoring clinical trial NCT06568003?
This trial is sponsored by Jenscare Innovation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06568003 being conducted?
This trial has 3 study locations across California, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.